Literature DB >> 33561308

Pulmonary hypertension is an important co-morbidity in developmental lung diseases of infancy: Bronchopulmonary dysplasia and congenital diaphragmatic hernia.

Nidhy Paulose Varghese1, Robert H Tillman2, Roberta L Keller3.   

Abstract

Bronchopulmonary dysplasia (BPD) following preterm birth and congenital diaphragmatic hernia (CDH) are both forms of developmental lung disease that may result in persistent pulmonary and pulmonary vascular morbidity in childhood. The pulmonary vascular disease (PVD) which accompanies BPD and CDH is due to developmental abnormalities and ongoing perinatal insults. This may be accompanied by evidence of elevated right heart pressures and pulmonary vascular resistance, leading to diagnosis of pulmonary hypertension (PH). The development of PH in these conditions is associated with increased morbidity and mortality in the vulnerable BPD and CDH populations. We present a review of PVD pathogenesis and evaluation in BPD and CDH and discuss management of related sequelae of PH co-morbidity for affected infants.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  bronchopulmonary dysplasia; congenital malformations; pulmonary hypertension; pulmonary physiology; pulmonary vascular disease

Mesh:

Year:  2021        PMID: 33561308     DOI: 10.1002/ppul.25258

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  2 in total

Review 1.  Cellular Origin(s) of Congenital Diaphragmatic Hernia.

Authors:  Gabriëla G Edel; Gerben Schaaf; Rene M H Wijnen; Dick Tibboel; Gabrielle Kardon; Robbert J Rottier
Journal:  Front Pediatr       Date:  2021-11-30       Impact factor: 3.418

2.  Building a dedicated pediatric pulmonary hypertension program: A consensus statement from the pediatric pulmonary hypertension network.

Authors:  Stephanie S Handler; Nidhy P Varghese; Erika B Rosenzweig; Delphine Yung; Usha Krishnan; Elise Whalen; Angela Bates; Catherine M Avitabile; Emma O Jackson; Russel Hirsch; Jeffrey Fineman; Steven H Abman
Journal:  Pulm Circ       Date:  2022-02-15       Impact factor: 2.886

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.